# EPCORE FL-1 (NCT05409066)

> Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05409066
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genmab
- Conditions: Follicular Lymphoma (FL)
- Interventions: Epcoritamab; Rituximab; Lenalidomide
- Enrollment: 549
- Primary outcome: Percentage of Participants Achieving Best Overall Response (BOR)
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- YouTube: 38
- Podcasts: 25
- X threads: 24
- X videos: 4

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=epcore-fl-1-nct05409066

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05409066", "email": "<work email>"}; the inbox owner confirms by the emailed link.